A Phase 2 interventional study of Mirabegron and Placebo in Lower Urinary Tract Symptoms and Bladder Outlet Obstruction, sponsored by Astellas Pharma Inc. Completed at 27 sites in 2 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2014-04-04.
Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment
This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.
416 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.
This study's enrollment of 200 is above the median of 100 across 272 interventional studies indexed under Lower Urinary Tract Symptoms.
Browse Lower Urinary Tract Symptoms studies →Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.
Drug: Placebo
Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.
Drug: Mirabegron
Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.
Drug: Mirabegron
oral
Also known as: YM178, Myrbetriq
oral
Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)
Maximum urinary flow rate (Qmax) was measured by the Investigator using cystometry and was sent to an independent central reading center for review and interpretation. Least squares means (LSM) were derived from an analysis of covariance (ANCOVA) model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Week 12
Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax)
Detrusor pressure at maximum urinary flow rate (PdetQmax) was measured by the Investigator using cystometry and was sent to an independent central reading center for review and interpretation. Least squares means (LSM) were derived from an analysis of covariance (ANCOVA) model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Week 12
Change From Baseline to End of Treatment in Bladder Contractile Index (BCI)
The Bladder Contractile Index (BCI) is a value used to measure the degree of contractility. BCI was calculated using the following formula: BCI = pdetQmax + 5Qmax. Strong contractility is a BCI \> 150, normal contractility is a BCI of 100-150 and weak contractility is a BCI of \< 100. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Week 12
Change From Baseline to End of Treatment in Bladder Voiding Efficiency (BVE)
Bladder Voiding Efficiency (BVE) is a product of bladder contractility against the urethral resistance and is measured according to the degree of bladder emptying. BVE is expressed as a percentage and is calculated using the formula: Bladder Voiding efficiency = (Voided volume x 100)/maximum cystometric capacity. A higher number indicates a higher voiding efficiency. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Week 12
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Postvoid Residual Volume (PVR)
Healthy micturitions (urinations) result in complete emptying of the bladder. Post Void Residual (PVR) is the volume of urine retained after voiding and was assessed using abdominal ultrasound. An increasing PVR over time is an indicator of abnormal bladder function or detrusor decompensation. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Weeks 1, 4, 8 and 12
Safety Assessed by Adverse Events (AEs), Electrocardiogram (ECG), Vital Signs, Physical Exam and Laboratory Tests
Abnormal laboratory parameters, vital signs or ECG data were defined as AEs if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A serious AE was an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important. AEs were assessed by the Investigator for intensity as mild, moderate or severe and for causal relationship to study drug.
Time frame: From first dose to within 30 days after last dose of double blind study medication (up to 16 weeks).
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Total Score
The IPSS is a validated global questionnaire used to assess the degree of "bother" from benign prostatic hyperplasia symptoms and is based on the answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Weeks 1, 4, 8 and 12
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Voiding Score
The IPSS is a validated global questionnaire used to assess the degree of "bother" from benign prostatic hyperplasia symptoms based on the answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The voiding score is the sum of the responses to 4 questions relating to urination (incomplete emptying, intermittency, weak stream and straining) and ranges from 0 to 20 (asymptomatic to very symptomatic). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Weeks 1, 4, 8 and 12
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Storage Symptom Score
The IPSS is a validated global questionnaire used to assess the degree of "bother" from benign prostatic hyperplasia symptoms based on the answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The storage symptom score is the sum of the responses to 3 questions relating to storage symptoms (frequency, urgency and nocturia) and ranges from 0 to 15 (asymptomatic to very symptomatic). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Weeks 1, 4, 8 and 12
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Patient Perception of Bladder Condition (PPBC)
The patient perception of bladder condition (PPBC) asks participants to assess their bladder condition using a 6-point validated Likert scale which ranges from 1 (does not cause me any problems at all) to 6 (causes me many severe problems). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Weeks 1, 4, 8 and 12
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Micturitions Per 24 Hours
A micturition is any voluntary urination, excluding episodes of incontinence only. The mean number of micturitions per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Weeks 1, 4, 8 and 12
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Urgency Episodes With Urgency Severity ≥ 3 Per 24 Hours
For each micturition and/or incontinence episode in the 3 days preceding the clinic visit, participants rated the degree of associated urgency (the sudden compelling desire to pass urine, which is difficult to defer) according to the following scale: 0: No Urgency, felt no need to empty my bladder but did so for another reason; 1: Mild Urgency, could postpone passing water for as long as necessary; 2: Moderate Urgency, could postpone passing water for a short while; 3: Severe Urgency, could not postpone passing water; 4: Urge Incontinence, leaked before reaching the toilet. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Weeks 1, 4, 8 and 12
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
The mean number of incontinence episodes (the involuntary leakage of urine) per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Weeks 1, 4, 8 and 12
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Voided Volume Per Micturition
The mean volume voided per micturition was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Weeks 1, 4, 8 and 12
Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptom (ICIQ MLUTS) Total Symptom Score
Male lower urinary tract symptoms were assessed by the ICIQ MaleLUTS questionnaire which consists of 13 questions each on a 0-4 scale (larger scores correspond to worse conditions). The total symptom score ranges from 0 to 52. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Weeks 4, 8 and 12
Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptom (ICIQ MLUTS) Total Bother Score
The degree to which urinary symptoms bothered participants was assessed by the ICIQ MaleLUTS questionnaire which consists of 13 symptom bother questions each on a 0-10 scale (larger scores correspond to worse outcomes). The total bother score ranges from 0 to 130. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Weeks 4, 8 and 12
Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Lower Urinary Tract Symptom Quality of Life (ICIQ-LUTSqol) Symptom Score
Quality of life was assessed by the ICIQ-LUTSqol questionnaire which consists of 19 questions each on a 1-4 scale (larger scores correspond to less quality of life). The total symptom score ranges from 19 - 76. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Weeks 4, 8 and 12
Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Lower Urinary Tract Symptom Quality of Life (ICIQ-LUTSqol) Overall Symptom Interference of Life Score
Participants were asked to rate how much their urinary symptoms interfered overall with their everyday life on a scale from 0 (not at all) to 10 (a great deal). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
Time frame: Baseline and Weeks 4, 8 and 12
| Milestone | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Started | 65 | 70 | 65 |
| Safety analysis set (saf) | 65 | 70 | 65 |
| Full analysis set (fas) | 63 | 64 | 58 |
| Completed | 63 | 67 | 58 |
| Not completed | 2 | 3 | 7 |
| Withdrew: Adverse event | 2 | 2 | 2 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Non-compliant with study procedures | 0 | 0 | 2 |
Maximum urinary flow rate (Qmax) was measured by the Investigator using cystometry and was sent to an independent central reading center for review and interpretation. Least squares means (LSM) were derived from an analysis of covariance (ANCOVA) model with the pooled study center and treatment as factors and the baseline value as a covariate.
| mL/sec | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax) | -0.33 ± 0.370 | 0.07 ± 0.366 | 0.30 ± 0.388 |
The Bladder Contractile Index (BCI) is a value used to measure the degree of contractility. BCI was calculated using the following formula: BCI = pdetQmax + 5Qmax. Strong contractility is a BCI \> 150, normal contractility is a BCI of 100-150 and weak contractility is a BCI of \< 100. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| Scores on a scale | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change From Baseline to End of Treatment in Bladder Contractile Index (BCI) | 1.25 ± 3.363 | -2.60 ± 3.324 | 2.51 ± 3.567 |
Detrusor pressure at maximum urinary flow rate (PdetQmax) was measured by the Investigator using cystometry and was sent to an independent central reading center for review and interpretation. Least squares means (LSM) were derived from an analysis of covariance (ANCOVA) model with the pooled study center and treatment as factors and the baseline value as a covariate.
| cmH2O | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax) | 2.92 ± 2.906 | -3.03 ± 2.872 | 1.53 ± 3.086 |
Bladder Voiding Efficiency (BVE) is a product of bladder contractility against the urethral resistance and is measured according to the degree of bladder emptying. BVE is expressed as a percentage and is calculated using the formula: Bladder Voiding efficiency = (Voided volume x 100)/maximum cystometric capacity. A higher number indicates a higher voiding efficiency. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| Percent voiding efficiency | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change From Baseline to End of Treatment in Bladder Voiding Efficiency (BVE) | -3.01 ± 3.163 | -5.49 ± 3.093 | 2.06 ± 3.277 |
Healthy micturitions (urinations) result in complete emptying of the bladder. Post Void Residual (PVR) is the volume of urine retained after voiding and was assessed using abdominal ultrasound. An increasing PVR over time is an indicator of abnormal bladder function or detrusor decompensation. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| mL | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change from Baseline at Week 1 [N=63; 66; 63] | -8.10 ± 6.512 | -2.93 ± 6.316 | 0.51 ± 6.480 |
| Change from Baseline at Week 4 [N=63; 67; 63] | 1.08 ± 6.734 | -1.03 ± 6.506 | 8.63 ± 6.702 |
| Change from Baseline at Week 8 [N=62; 67; 61] | -9.92 ± 6.922 | 5.11 ± 6.621 | -3.71 ± 6.972 |
| Change from Baseline at Week 12 [N=59; 63; 57] | 4.65 ± 11.598 | 21.13 ± 11.235 | 33.22 ± 11.822 |
| Change from Baseline at EOT [N=64; 70; 65] | 0.55 ± 10.702 | 17.89 ± 10.190 | 30.77 ± 10.598 |
Abnormal laboratory parameters, vital signs or ECG data were defined as AEs if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A serious AE was an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important. AEs were assessed by the Investigator for intensity as mild, moderate or severe and for causal relationship to study drug.
| participants | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Adverse events | 28 | 28 | 34 |
| Mild intensity adverse events | 17 | 16 | 20 |
| Moderate intensity adverse events | 7 | 10 | 14 |
| Severe intensity adverse events | 4 | 2 | 0 |
| Drug-related adverse events | 8 | 5 | 11 |
| Serious adverse events | 0 | 0 | 0 |
| AEs leading to study drug discontinuation | 2 | 1 | 2 |
| Deaths | 0 | 0 | 0 |
The IPSS is a validated global questionnaire used to assess the degree of "bother" from benign prostatic hyperplasia symptoms and is based on the answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| scores on a scale | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change from Baseline at Week 1 [N=63; 63; 57] | -1.7 ± 0.47 | -2.4 ± 0.47 | -1.6 ± 0.50 |
| Change from Baseline at Week 4 [N=63; 62; 58] | -4.0 ± 0.62 | -5.2 ± 0.62 | -4.4 ± 0.66 |
| Change from Baseline at Week 8 [N=62; 63; 56] | -5.0 ± 0.68 | -6.3 ± 0.68 | -5.3 ± 0.73 |
| Change from Baseline at Week 12 [N=58; 61; 52] | -5.2 ± 0.83 | -6.3 ± 0.81 | -4.8 ± 0.89 |
| Change from Baseline at EOT [N=63; 64; 58] | -5.0 ± 0.78 | -6.2 ± 0.77 | -4.8 ± 0.83 |
The IPSS is a validated global questionnaire used to assess the degree of "bother" from benign prostatic hyperplasia symptoms based on the answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The voiding score is the sum of the responses to 4 questions relating to urination (incomplete emptying, intermittency, weak stream and straining) and ranges from 0 to 20 (asymptomatic to very symptomatic). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| scores on a scale | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change from Baseline at Week 1 [N=63; 63; 57] | -0.9 ± 0.33 | -1.0 ± 0.33 | -0.5 ± 0.35 |
| Change from Baseline at Week 4 [N=63; 62; 58] | -2.3 ± 0.41 | -2.5 ± 0.41 | -2.1 ± 0.43 |
| Change from Baseline at Week 8 [N=62; 63; 56] | -3.0 ± 0.44 | -3.1 ± 0.43 | -2.7 ± 0.47 |
| Change from Baseline at Week 12 [N=58; 61; 52] | -3.0 ± 0.55 | -2.9 ± 0.53 | -2.3 ± 0.58 |
| Change from Baseline at EOT [N=63; 64; 58] | -2.8 ± 0.52 | -2.9 ± 0.51 | -2.4 ± 0.54 |
The IPSS is a validated global questionnaire used to assess the degree of "bother" from benign prostatic hyperplasia symptoms based on the answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The storage symptom score is the sum of the responses to 3 questions relating to storage symptoms (frequency, urgency and nocturia) and ranges from 0 to 15 (asymptomatic to very symptomatic). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| scores on a scale | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change from Baseline at Week 1 [N=63; 63; 57] | -0.7 ± 0.25 | -1.4 ± 0.25 | -1.0 ± 0.26 |
| Change from Baseline at Week 4 [N=63; 62; 58] | -1.7 ± 0.31 | -2.6 ± 0.31 | -2.3 ± 0.33 |
| Change from Baseline at Week 8 [N=62; 63; 57] | -2.1 ± 0.33 | -3.2 ± 0.32 | -2.6 ± 0.35 |
| Change from Baseline at Week 12 [N=59; 61; 52] | -2.2 ± 0.36 | -3.4 ± 0.35 | -2.5 ± 0.39 |
| Change from Baseline at EOT [N=63; 64; 58] | -2.2 ± 0.34 | -3.3 ± 0.34 | -2.5 ± 0.36 |
The patient perception of bladder condition (PPBC) asks participants to assess their bladder condition using a 6-point validated Likert scale which ranges from 1 (does not cause me any problems at all) to 6 (causes me many severe problems). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| scores on a scale | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change from Baseline at Week 1 [N=63; 63; 57] | -0.2 ± 0.10 | -0.3 ± 0.09 | -0.6 ± 0.10 |
| Change from Baseline at Week 4 [N=63; 62; 58] | -0.3 ± 0.11 | -0.5 ± 0.11 | -0.6 ± 0.12 |
| Change from Baseline at Week 8 [N=62; 63; 57] | -0.5 ± 0.12 | -0.7 ± 0.12 | -0.9 ± 0.12 |
| Change from Baseline at Week 12 [N=60; 61; 53] | -0.6 ± 0.13 | -0.9 ± 0.13 | -0.9 ± 0.14 |
| Change from Baseline at EOT [N=63; 64; 58] | -0.6 ± 0.13 | -0.9 ± 0.13 | -0.8 ± 0.13 |
A micturition is any voluntary urination, excluding episodes of incontinence only. The mean number of micturitions per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| micturitions | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change from Baseline at Week 1 [N=63; 64; 57] | -0.15 ± 0.295 | -0.58 ± 0.291 | -0.48 ± 0.311 |
| Change from Baseline at Week 4 [N=63; 64; 58] | -0.36 ± 0.333 | -0.90 ± 0.328 | -1.36 ± 0.347 |
| Change from Baseline at Week 8 [N=62; 63; 57] | -0.61 ± 0.337 | -1.32 ± 0.333 | -1.41 ± 0.352 |
| Change from Baseline at Week 12 [N=62; 63; 54] | -0.27 ± 0.322 | -1.33 ± 0.318 | -1.23 ± 0.348 |
| Change from Baseline at EOT [N=63; 64; 58] | -0.31 ± 0.317 | -1.35 ± 0.313 | -1.37 ± 0.331 |
For each micturition and/or incontinence episode in the 3 days preceding the clinic visit, participants rated the degree of associated urgency (the sudden compelling desire to pass urine, which is difficult to defer) according to the following scale: 0: No Urgency, felt no need to empty my bladder but did so for another reason; 1: Mild Urgency, could postpone passing water for as long as necessary; 2: Moderate Urgency, could postpone passing water for a short while; 3: Severe Urgency, could not postpone passing water; 4: Urge Incontinence, leaked before reaching the toilet. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| Urgency episodes | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change from Baseline at Week 1 [N=63; 64; 57] | 0.09 ± 0.256 | -0.81 ± 0.253 | -0.60 ± 0.271 |
| Change from Baseline at Week 4 [N=63; 64; 58] | -0.11 ± 0.284 | -1.13 ± 0.281 | -0.95 ± 0.298 |
| Change from Baseline at Week 8 [N=62; 63; 57] | -0.35 ± 0.288 | -1.43 ± 0.285 | -0.98 ± 0.302 |
| Change from Baseline at Week 12 [N=62; 63; 54] | -0.33 ± 0.295 | -1.65 ± 0.292 | -0.90 ± 0.320 |
| Change from Baseline at EOT [N=63; 64; 58] | -0.33 ± 0.290 | -1.60 ± 0.287 | -0.93 ± 0.304 |
The mean number of incontinence episodes (the involuntary leakage of urine) per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| Incontinence episodes | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change from Baseline at Week 1 [N=9; 18; 13] | -1.16 ± 0.561 | -0.18 ± 0.386 | -0.97 ± 0.516 |
| Change from Baseline at Week 4 [N=9; 18; 13 | -0.99 ± 0.638 | -0.42 ± 0.439 | -1.60 ± 0.586 |
| Change from Baseline at Week 8 [N=9; 17; 13] | -0.77 ± 0.558 | -0.70 ± 0.396 | -2.31 ± 0.513 |
| Change from Baseline at Week 12 [N=9; 17; 13] | -0.98 ± 0.528 | -0.91 ± 0.374 | -2.03 ± 0.485 |
| Change from Baseline at EOT [N=9; 18; 13] | -0.96 ± 0.516 | -0.89 ± 0.355 | -1.98 ± 0.474 |
The mean volume voided per micturition was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| mL | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change from Baseline at Week 1 [N=63; 64; 57] | 2.75 ± 4.580 | 6.71 ± 4.508 | 10.38 ± 4.833 |
| Change from Baseline at Week 4 [N=63; 64; 58] | 10.25 ± 4.779 | 12.55 ± 4.705 | 18.31 ± 5.001 |
| Change from Baseline at Week 8 [N=62; 63; 57] | 4.53 ± 4.930 | 14.52 ± 4.859 | 22.83 ± 5.163 |
| Change from Baseline at Week 12 [N=62; 63; 54] | 4.49 ± 4.610 | 16.62 ± 4.549 | 16.20 ± 5.000 |
| Change from Baseline at EOT [N=63; 64; 58] | 5.40 ± 4.608 | 15.82 ± 4.537 | 15.80 ± 4.823 |
Male lower urinary tract symptoms were assessed by the ICIQ MaleLUTS questionnaire which consists of 13 questions each on a 0-4 scale (larger scores correspond to worse conditions). The total symptom score ranges from 0 to 52. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| scores on a scale | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change from Baseline at Week 4 [N=60; 60; 58] | -2.8 ± 0.61 | -4.0 ± 0.61 | -3.5 ± 0.63 |
| Change from Baseline at Week 8 [N=61; 61; 56] | -3.9 ± 0.65 | -5.1 ± 0.65 | -4.9 ± 0.68 |
| Change from Baseline at Week 12 [N=58; 60; 53] | -4.2 ± 0.76 | -4.9 ± 0.74 | -5.4 ± 0.80 |
| Change from Baseline at EOT [N=62; 61; 58] | -3.9 ± 0.73 | -4.8 ± 0.73 | -5.5 ± 0.75 |
The degree to which urinary symptoms bothered participants was assessed by the ICIQ MaleLUTS questionnaire which consists of 13 symptom bother questions each on a 0-10 scale (larger scores correspond to worse outcomes). The total bother score ranges from 0 to 130. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| scores on a scale | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change from Baseline at Week 4 [N=58; 53; 56] | -7.5 ± 2.71 | -13.6 ± 2.82 | -10.0 ± 2.75 |
| Change from Baseline at Week 8 [N=57; 57; 53] | -11.6 ± 2.77 | -21.9 ± 2.76 | -19.3 ± 2.86 |
| Change from Baseline at Week 12 [N=54; 53; 51] | -15.1 ± 3.32 | -19.3 ± 3.35 | -17.4 ± 3.44 |
| Change from Baseline at EOT [N=60; 57; 58] | -14.0 ± 3.15 | -20.1 ± 3.21 | -18.6 ± 3.20 |
Quality of life was assessed by the ICIQ-LUTSqol questionnaire which consists of 19 questions each on a 1-4 scale (larger scores correspond to less quality of life). The total symptom score ranges from 19 - 76. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| scores on a scale | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change from Baseline at Week 4 [N=41; 37; 33] | -3.2 ± 0.97 | -4.1 ± 1.03 | -3.1 ± 1.13 |
| Change from Baseline at Week 8 [N=39; 36; 31] | -4.8 ± 1.03 | -6.4 ± 1.06 | -5.7 ± 1.18 |
| Change from Baseline at Week 12 [N=40; 30;26] | -4.7 ± 1.11 | -6.9 ± 1.29 | -5.7 ± 1.47 |
| Change from Baseline at EOT [N=47; 40; 36] | -4.8 ± 0.95 | -6.9 ± 1.03 | -5.0 ± 1.11 |
Participants were asked to rate how much their urinary symptoms interfered overall with their everyday life on a scale from 0 (not at all) to 10 (a great deal). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.
| scores on a scale | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| Change from Baseline at Week 4 [N=61; 62; 58] | -0.4 ± 0.26 | -1.2 ± 0.26 | -1.0 ± 0.27 |
| Change from Baseline at Week 8 [N=60; 63; 57] | -0.9 ± 0.27 | -1.7 ± 0.26 | -1.7 ± 0.28 |
| Change from Baseline at Week 12 [N=59; 61; 53] | -1.1 ± 0.30 | -2.1 ± 0.29 | -1.9 ± 0.32 |
| Change from Baseline at EOT [N=62; 63; 58] | -1.1 ± 0.29 | -2.0 ± 0.28 | -1.9 ± 0.30 |
Collected over From first dose to within 30 days after last dose of double blind study medication (up to 16 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/65 (0%) | 1/65 (1.5%) |
| Mirabegron 50 mg | — | 0/70 (0%) | 4/70 (5.7%) |
| Mirabegron 100 mg | — | 0/65 (0%) | 2/65 (3.1%) |
| Event | Placebo | Mirabegron 50 mg | Mirabegron 100 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/65 | 4/70 | 2/65 |
| Age, Continuous(years) | Placebo | Mirabegron 50 mg | Mirabegron 100 mg | Total |
|---|---|---|---|---|
| Mean | 61.2 ± 8.43 | 64.1 ± 8.82 | 62.6 ± 9.92 | 62.7 ± 9.10 |
| Sex: Female, Male(Participants) | Placebo | Mirabegron 50 mg | Mirabegron 100 mg | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 65 | 70 | 65 | 200 |
| Race/Ethnicity, Customized(participants) | Placebo | Mirabegron 50 mg | Mirabegron 100 mg | Total |
|---|---|---|---|---|
| White | 56 | 60 | 59 | 175 |
| Black or African American | 6 | 6 | 4 | 16 |
| Asian | 1 | 3 | 2 | 6 |
| American Indian or Alaskan native | 1 | 0 | 0 | 1 |
| Other | 1 | 1 | 0 | 2 |
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirabegron
Lower Urinary Tract Symptoms →